22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC

Barclays PLC bought a new stake in shares of CureVac (NASDAQ:CVAC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 22,946 shares of the company’s stock, valued at approximately $67,000.

A number of other hedge funds also recently made changes to their positions in the business. Private Advisor Group LLC bought a new stake in CureVac in the third quarter worth about $30,000. International Assets Investment Management LLC bought a new stake in shares of CureVac in the 3rd quarter worth approximately $35,000. Integrated Wealth Concepts LLC purchased a new position in CureVac in the third quarter valued at approximately $35,000. Bank of New York Mellon Corp bought a new position in CureVac during the second quarter valued at $54,000. Finally, Ballentine Partners LLC increased its position in CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock worth $67,000 after buying an additional 8,406 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors.

CureVac Price Performance

NASDAQ CVAC opened at $3.85 on Friday. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The company has a market cap of $861.94 million, a PE ratio of 7.00 and a beta of 2.50. CureVac has a 52 week low of $2.21 and a 52 week high of $5.28. The firm’s 50-day simple moving average is $3.31 and its two-hundred day simple moving average is $3.19.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.